Literature DB >> 25982281

Opportunities and challenges provided by crosstalk between signalling pathways in cancer.

A Prahallad1, R Bernards1.   

Abstract

During evolution, connections between the major signalling pathways were established to provide cells with an ability to deal with perturbations of homeostasis. However, these feedback and crosstalk mechanisms can become a liability in the treatment of cancer, as the inhibition of one cancer-relevant signalling pathway can lead to the activation of a secondary survival pathway that interferes with cancer drug efficacy. In this review, we discuss connections between signalling pathways in relation to cancer therapy and we evaluate the use of genetic approaches to identify pathway crosstalk. We also discuss how insight into connections between signalling pathways can be exploited to design powerful synthetic lethal drug combination therapies for the treatment of cancer.

Entities:  

Mesh:

Year:  2015        PMID: 25982281     DOI: 10.1038/onc.2015.151

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  71 in total

Review 1.  Drug rechallenge and treatment beyond progression--implications for drug resistance.

Authors:  Elizabeth A Kuczynski; Daniel J Sargent; Axel Grothey; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

Review 2.  Strategies for optimizing combinations of molecularly targeted anticancer agents.

Authors:  Janet E Dancey; Helen X Chen
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

Review 3.  Reading between the lines; understanding drug response in the post genomic era.

Authors:  Constantine C Alifrangis; Ultan McDermott
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

4.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

Review 5.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

Review 6.  The tumour microenvironment as a target for chemoprevention.

Authors:  Adriana Albini; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

7.  Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

Authors:  Giorgia Migliardi; Francesco Sassi; Davide Torti; Francesco Galimi; Eugenia R Zanella; Michela Buscarino; Dario Ribero; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Mauro Risio; Lorenzo Capussotti; Silvia Marsoni; Federica Di Nicolantonio; Alberto Bardelli; Paolo M Comoglio; Livio Trusolino; Andrea Bertotti
Journal:  Clin Cancer Res       Date:  2012-03-05       Impact factor: 12.531

Review 8.  Romidepsin: a novel histone deacetylase inhibitor for cancer.

Authors:  Erin M Bertino; Gregory A Otterson
Journal:  Expert Opin Investig Drugs       Date:  2011-06-24       Impact factor: 6.206

Review 9.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Authors:  Alberto Bardelli; Salvatore Siena
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

Review 10.  Epigenetic modifications as therapeutic targets.

Authors:  Theresa K Kelly; Daniel D De Carvalho; Peter A Jones
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

View more
  15 in total

1.  Drug therapy: Exploiting synthetic lethality to improve cancer therapy.

Authors:  Diede Brunen; René Bernards
Journal:  Nat Rev Clin Oncol       Date:  2017-03-29       Impact factor: 66.675

Review 2.  Targeting "undruggable" c-Myc protein by synthetic lethality.

Authors:  Chen Wang; Hui Fang; Jiawei Zhang; Ying Gu
Journal:  Front Med       Date:  2021-03-04       Impact factor: 4.592

3.  The NF-κB pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells.

Authors:  Bingyi Tan; Zenong Yuan; Qingyu Zhang; Xu Xiqiang; Jun Dong
Journal:  J Appl Biomed       Date:  2021-09-24       Impact factor: 1.797

4.  Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens.

Authors:  Rajarshi Guha; Lesley A Mathews Griner; Jonathan M Keller; Xiaohu Zhang; David Fitzgerald; Antonella Antignani; Ira Pastan; Craig J Thomas; Marc Ferrer
Journal:  J Biomol Screen       Date:  2016-04-25

Review 5.  Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases.

Authors:  Benjamin Wooden; Nicolas Goossens; Yujin Hoshida; Scott L Friedman
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 33.883

Review 6.  Immuno-Oncology Integrative Networks: Elucidating the Influences of Osteosarcoma Phenotypes.

Authors:  Ankush Sharma; Enrico Capobianco
Journal:  Cancer Inform       Date:  2017-07-26

7.  In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.

Authors:  Qianxiang Zhou; Yali Chen; Xi Chen; Wennan Zhao; Yuxu Zhong; Ran Wang; Meihua Jin; Yuling Qiu; Dexin Kong
Journal:  Int J Biol Sci       Date:  2016-04-08       Impact factor: 6.580

Review 8.  WNT Signaling in Disease.

Authors:  Li Fang Ng; Prameet Kaur; Nawat Bunnag; Jahnavi Suresh; Isabelle Chiao Han Sung; Qian Hui Tan; Jan Gruber; Nicholas S Tolwinski
Journal:  Cells       Date:  2019-08-03       Impact factor: 6.600

Review 9.  The Role of Nrf2 Activity in Cancer Development and Progression.

Authors:  Alina-Andreea Zimta; Diana Cenariu; Alexandru Irimie; Lorand Magdo; Seyed Mohammad Nabavi; Atanas G Atanasov; Ioana Berindan-Neagoe
Journal:  Cancers (Basel)       Date:  2019-11-08       Impact factor: 6.639

10.  RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.

Authors:  Meng Zhang; Senlin Zhao; Cong Tan; Yanzi Gu; Xuefeng He; Xiang Du; Dawei Li; Ping Wei
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.